AGC to manufacture Takara Bio's COVID-19 vaccine

By The Science Advisory Board staff writers

May 21, 2020 -- In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid DNA intermediates for a DNA SARS-CoV-2 vaccine, according to the firms.

The vaccine will be developed based on Osaka University and AnGes plasmid DNA products. AGC will bring over 10 years of expertise in plasmid production to the project and will leverage its manufacturing facilities in Asia, Europe, and the U.S.

The companies did not release expected development timelines.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?